Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Where to go with new expensive treatments in NSCLC.

Literature DB >> 9683287

Where to go with new expensive treatments in NSCLC.

A Webb¹, M E O'Brien.

Abstract

Entities: Disease

Mesh：

Year: 1998 PMID： 9683287 PMCID： PMC2062890 DOI： 10.1038/bjc.1998.458

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

× No keyword cloud information.

14 in total

1. Regulating the pharmaceutical industry.

Authors: A Maynard; K Bloor
Journal: BMJ Date: 1997-07-26

2. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma.

Authors: J Klastersky; J P Sculier; P Ravez; P Libert; J Michel; G Vandermoten; P Rocmans; Y Bonduelle; M Mairesse; T Michiels
Journal: J Clin Oncol Date: 1986-12 Impact factor: 44.544

3. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.

Authors: B Fisher; J Dignam; N Wolmark; A DeCillis; B Emir; D L Wickerham; J Bryant; N V Dimitrov; N Abramson; J N Atkins; H Shibata; L Deschenes; R G Margolese
Journal: J Natl Cancer Inst Date: 1997-11-19 Impact factor: 13.506

Review 4. Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions.

Authors: P A Bunn
Journal: Semin Oncol Date: 1997-08 Impact factor: 4.929

5. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

Authors: R Rosell; J Gómez-Codina; C Camps; J Maestre; J Padille; A Cantó; J L Mate; S Li; J Roig; A Olazábal
Journal: N Engl J Med Date: 1994-01-20 Impact factor: 91.245

6. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group.

Authors: D R Gandara; J Crowley; R B Livingston; E A Perez; C W Taylor; G Weiss; J R Neefe; L F Hutchins; R W Roach; S M Grunberg
Journal: J Clin Oncol Date: 1993-05 Impact factor: 44.544

7. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.

Authors: M Fukuoka; H Niitani; A Suzuki; M Motomiya; K Hasegawa; Y Nishiwaki; T Kuriyama; Y Ariyoshi; S Negoro; N Masuda
Journal: J Clin Oncol Date: 1992-01 Impact factor: 44.544

8. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules.

Authors: R J Gralla; E S Casper; D P Kelsen; D W Braun; M E Dukeman; N Martini; C W Young; R B Golbey
Journal: Ann Intern Med Date: 1981-10 Impact factor: 25.391

9. Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer [seecomments].

Authors: A Yokoyama; Y Kurita; N Saijo; T Tamura; K Noda; K Shimokata; T Matsuda
Journal: Br J Cancer Date: 1998-07 Impact factor: 7.640

10. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group.

Authors: N Masuda; M Fukuoka; A Fujita; Y Kurita; S Tsuchiya; K Nagao; S Negoro; H Nishikawa; N Katakami; K Nakagawa; H Niitani
Journal: Br J Cancer Date: 1998-07 Impact factor: 7.640

2 in total

1. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.

Authors: M E O'Brien; A Saini; I E Smith; A Webb; K Gregory; R Mendes; C Ryan; K Priest; K V Bromelow; R D Palmer; N Tuckwell; D A Kennard; B E Souberbielle
Journal: Br J Cancer Date: 2000-10 Impact factor: 7.640

2. Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study.

Authors: V Georgoulias; A Agelidou; K Syrigos; A Rapti; M Agelidou; J Nikolakopoulos; A Polyzos; A Athanasiadis; E Tselepatiotis; N Androulakis; K Kalbakis; G Samonis; D Mavroudis
Journal: Br J Cancer Date: 2005-10-03 Impact factor: 7.640

2 in total